Need support when going through breast cancer?
It is so very hard when someone is diagnosed with breast cancer. Not only does it effect the patient, but so many other family members and friends.
Online support can be a major help to those being effected by this disease.
For further information please visit
http://www.friendsinneed.com
About the author:
Susan Pangallo is the creator of the online support forum Friends in Need. She is also an eleven survivor of breast cancer and can give support and strength to those effected.
http://www.friendsinneed.com
Written by: susan
|
Updates and Recent News
New Data Demonstrate Significant Improvement In Progression-Free Survival For Triple Negative Metastatic Breast Cancer Patients Treated with IXEMPRA Plus Capecitabine
SAN ANTONIO -- Bristol-Myers Squibb Company today announced new data from studies of IXEMPRA(TM) (ixabepilone) plus capecitabine compared to capectabine alone, including a pre-specified sub set analysis demonstrating a significant increase in progression free survival (PFS) in patients with triple negative breast cancer. The study results - which are from a pooled analysis of approximately 2,000 patients enrolled in two Phase III clinical trials of IXEMPRA (046 and 048) - were presented today at the 2008 San Antonio Breast Cancer Symposium (SABCS). Patients studied were either resistant to or pretreated with anthracyclines and taxanes. In the pooled analysis of the subset of 443 patients with triple negative breast cancer.
To Read More...
Molecular Breast Imaging Identifies Occult Cancer
Breast-Specific Gamma Imaging (BSGI) is shown to be an effective method of identifying mammographically and clinically occult (hidden) breast cancer. BSGI is a molecular breast imaging technique that can see lesions independent of tissue density and discover very early stage cancers. According to findings presented today at the annual meeting of the Radiological Society of North America (RSNA) in this study of women where breast cancer was already suspected via mammogram or physical exam, BSGI identified additional suspicious lesions in 29 percent of the patients and found a previously unsuspected cancer in 9 percent of women. "BSGI is an emerging technology that goes beyond mammography as an effective imaging procedure for early breast.
To Read More...
Wyeth Announces Positive Data From Phase 2 Study Of Neratinib In Advanced HER-2-Positive Breast Cancer
COLLEGEVILLE, Pa. -- Wyeth Pharmaceuticals, a division of Wyeth, today announced data from an open-label phase 2 clinical trial of neratinib (HKI-272) in women with advanced HER-2-positive breast cancer. These data suggest that neratinib has antitumor activity in patients with advanced breast cancer positive for the ErbB-2 receptor (also known as HER-2 or Neu). These data were presented today during an oral session at the CTRC-AACR San Antonio Breast Cancer Symposium. Neratinib is an investigational orally-administered potent and irreversible dual inhibitor of the HER-2 and EGFR kinases. Wyeth expects to initiate the first study in a global phase 3 program for neratinib in advanced HER-2-positive breast cancer later this.
To Read More...
|
